Abstract
The aims of this study were as follows: (1) to analyze clinical, histopathologic characteristics, treatment outcome, and prognostic factors of patients with follicular large-cell lymphoma (FLCL); and (2) to compare them with those of patients with diffuse large B-cell lymphoma (DLCL) treated in the same therapeutic trial. Eighty-nine FLCL patients who were histologically reviewed and who received an intensive chemotherapy regimen according to the LNH 87 protocol were analyzed and compared with 1,096 B-cell DLCL patients included in the same protocol. After intensive induction treatment, 59 patients (67%) achieved a complete remission [CR]. Estimated 5-year survival was 59%, and estimated 5-year freedom from progression (FFP) was 39%. Prognostic factors associated with shorter FFP were age greater than 60 years (P = .02), advanced clinical stage (P = .01), abnormal lactic dehydrogenase (LDH) level (P = .02), abnormal beta-2 microglobulin (P = .02), B symptoms (P = .03), bone marrow involvement (P = .04), and high expression of bcl-2 protein (P = .05). When compared with B-cell DLCL patients, FLCL patients were younger (P = .02), had a better Eastern Cooperative Oncology Group (ECOG) status (P = .05), less bulky mass (P = .04), m...Continue Reading
Citations
Aug 15, 2000·American Journal of Clinical Pathology·D B CornfieldR C Braylan
Aug 12, 2006·Current Oncology Reports·Andrew J Davies
Oct 11, 2007·Leukemia & Lymphoma·Christos Emmanouilides
Sep 1, 2007·Current Opinion in Oncology·Philip J Bierman
Feb 26, 2008·Leukemia & Lymphoma·Lesley ChristieJohn Goodlad
Oct 1, 2007·Current Hematologic Malignancy Reports·Brian K Link
Apr 3, 2013·Leukemia·M WangL Fayad
Jan 11, 2018·The Oncologist·Patrizia MondelloMichael Mian
Jul 3, 2003·British Journal of Cancer·I ChauD Catovsky
Sep 25, 2002·European Journal of Haematology·Gerald JäegerHeinz Sill
Dec 16, 2000·The American Journal of Surgical Pathology·M TakeshitaM Kikuchi
Aug 13, 2003·Hematology·J C EwingM J Mackie
Oct 9, 2007·Bone Marrow Transplantation·R N PhamA K Gopal
Jun 1, 2009·Expert Review of Hematology·Peter McLaughlin
Dec 1, 2011·British Journal of Haematology·Björn E WahlinBirgitta Sander
Mar 20, 2016·Blood·James O Armitage, Dan L Longo
Apr 28, 2000·Leukemia & Lymphoma·D D WeisenburgerW G Sanger
May 10, 2001·International Journal of Hematology·E KondoY Morishima
Dec 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce A PetersonArlan J Gottlieb
Oct 13, 2012·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Fredrick B Hagemeister
Jul 9, 2013·The Cochrane Database of Systematic Reviews·Gilad ItchakiMical Paul
Jan 10, 2002·Blood·Brunangelo Falini, David Y Mason
May 3, 2002·Blood·German OttHans Konrad Müller-Hermelink
Feb 13, 2003·British Journal of Haematology·Douglas E HorsmanRandy D Gascoyne
Apr 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas RelanderRandy D Gascoyne
Oct 12, 2013·Cancer Science·Eri YamamotoYoshiaki Ishigatsubo
Nov 9, 2002·Blood·Christine P HansJames O Armitage
Jan 17, 2003·Blood·Anneke G Bosga-BouwerSibrand Poppema
Oct 15, 2008·Leukemia & Lymphoma·Christian BuskeWyndham Wilson
Apr 13, 2004·Oncogene·Klaus-Michael Debatin, Peter H Krammer
May 2, 2008·Journal of Neurosurgery·Sang-Hoon YoonHee-Won Jung
Mar 12, 2021·British Journal of Haematology·Allison BarracloughEliza A Hawkes
Mar 10, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A K GantiJ O Armitage
Dec 18, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M J OvermanL E Fayad
Nov 11, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J ShustikL H Sehn